InvestorsHub Logo
Followers 3
Posts 789
Boards Moderated 0
Alias Born 01/10/2010

Re: None

Monday, 01/23/2012 11:17:14 PM

Monday, January 23, 2012 11:17:14 PM

Post# of 7601
Can Geron Recover in 2012?

http://www.fool.com/investing/high-growth/2012/01/20/can-geron-recover-in-2012.aspx

In addition to getting out of a controversial area, Geron will also save millions in research costs, as it expects to cut almost 40% of its workforce as a result of the move. Moreover, if the company is able to sell its stem-cell division to another buyer, it could bring in extra cash, which would be useful for clinical trials going forward. With their own stem-cell programs, Pfizer (NYSE: PFE ) or GlaxoSmithKline (NYSE: GSK ) could find the old Geron program a useful addition.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GERN News